Q2
ATAI — Q2 2026 Financial Report Analysis
AtaiBeckley's operating loss widened 75% to $44.1M as R&D more than doubled with BPL-003 entering Phase 3; it ended June with $191.8M in cash and securities and was acquired by Eli Lilly for $6.75/share plus a CVR in September 2026.